- Complications
- Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study
-
Yoo-Ri Chung, Kyoung Hwa Ha, Hyeon Chang Kim, Sang Jun Park, Kihwang Lee, Dae Jung Kim
-
Diabetes Metab J. 2019;43(5):640-648. Published online February 20, 2019
-
DOI: https://doi.org/10.4093/dmj.2018.0137
-
-
6,228
View
-
81
Download
-
21
Web of Science
-
21
Crossref
-
 Abstract
 PDF Supplementary Material PubReader
- Background
To investigate the effects of dipeptidyl peptidase-4 inhibitor (DPP4i) as add-on medications to metformin on progression of diabetic retinopathy (DR) in patients with type 2 diabetes mellitus, compared with sulfonylurea (SU) or thiazolidinedione (TZD). MethodsWe identified 4,447 patients with DPP4i, 6,136 with SU, and 617 with TZD in addition to metformin therapy from the database of Korean National Health Insurance Service between January 2013 and December 2015. Cox proportional hazards regression models were used to calculate hazard ratios (HRs) for DR progression. The progression of DR was defined by the procedure code of panretinal photocoagulation, intravitreal injection or vitrectomy; or the addition of diagnostic code of vitreous hemorrhage, retinal detachment, or neovascular glaucoma. ResultsThe age and sex-adjusted HR of DR progression was 0.74 for DPP4i add-on group compared with SU add-on group (95% confidence interval [CI], 0.62 to 0.89). This lower risk of DR progression remained significant after additional adjustments for comorbidities, duration of metformin therapy, intravitreal injections and calendar index year (HR, 0.80; 95% CI, 0.66 to 0.97). ConclusionThis population-based cohort study showed that the use of DPP4i as add-on therapy to metformin did not increase the risk of DR progression compared to SU.
-
Citations
Citations to this article as recorded by  - Sodium-Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Glaucoma in Patients With Type 2 Diabetes: A Target Trial Emulation
Kathleen Eng, Nazlee Zebardast, Michael V. Boland, Jui-En Lo, Swarup S. Swaminathan, David S. Friedman, Kevin Sheng-Kai Ma
American Journal of Ophthalmology.2025; 271: 286. CrossRef - Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review
Dimitrios P. Ntentakis, Victor San Martin Carvalho Correa, Anastasia Maria Ntentaki, Eleni Delavogia, Toshio Narimatsu, Nikolaos E. Efstathiou, Demetrios G. Vavvas
Graefe's Archive for Clinical and Experimental Ophthalmology.2024; 262(3): 717. CrossRef - Incretin‐based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta‐analysis of observational studies
Samuel Igweokpala, Naheemot Olaoluwa Sule, Antonios Douros, Oriana H. Y. Yu, Kristian B. Filion
Diabetes, Obesity and Metabolism.2024; 26(2): 721. CrossRef - Weight loss, bariatric surgery, and novel antidiabetic drugs effects on diabetic retinopathy: a review
Alejandro M. Perez, Emily Neag, Jayanth Sridhar, Basil K. Williams
Current Opinion in Ophthalmology.2024; 35(3): 192. CrossRef - Role of Systemic Factors in Improving the Prognosis of Diabetic Retinal Disease and Predicting Response to Diabetic Retinopathy Treatment
Joe Mellor, Anita Jeyam, Joline W.J. Beulens, Sanjeeb Bhandari, Geoffrey Broadhead, Emily Chew, Ward Fickweiler, Amber van der Heijden, Daniel Gordin, Rafael Simó, Janet Snell-Bergeon, Anniina Tynjälä, Helen Colhoun
Ophthalmology Science.2024; 4(4): 100494. CrossRef - Novel Antidiabetic Drugs and the Risk of Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Artur Małyszczak, Joanna Przeździecka-Dołyk, Urszula Szydełko-Paśko, Marta Misiuk-Hojło
Journal of Clinical Medicine.2024; 13(6): 1797. CrossRef - Association between dipeptidyl peptidase-4 inhibitor use and diabetic retinopathy: a systematic review and meta-analysis of real-world studies
Minxi Wang, Jiali Lu, Jiyue Dong
BMC Ophthalmology.2024;[Epub] CrossRef - Incidence and progression of diabetic retinopathy in patients treated with glucagon‐like peptide‐1 receptor agonists versus sodium‐glucose cotransporter 2 inhibitors: A population‐based cohort study
Donna Shu‐Han Lin, Hao‐Yun Lo, Kuan‐Chih Huang, Ting‐Tse Lin, Jen‐Kuang Lee, Lian‐Yu Lin
Diabetes, Obesity and Metabolism.2024; 26(10): 4386. CrossRef - Ocular and Plasma Pharmacokinetics of Sitagliptin Eye Drops: Preclinical Data
Cristina Hernández, Hugo Ramos, Anne Létondor, Rafael Simó
Pharmaceuticals.2024; 17(12): 1579. CrossRef - Sitagliptin eye drops prevent the impairment of retinal neurovascular unit in the new Trpv2+/− rat model
Hugo Ramos, Josy Augustine, Burak M. Karan, Cristina Hernández, Alan W. Stitt, Tim M. Curtis, Rafael Simó
Journal of Neuroinflammation.2024;[Epub] CrossRef - Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy
Jennifer Perais, Ridhi Agarwal, Jennifer R Evans, Emma Loveman, Jill L Colquitt, David Owens, Ruth E Hogg, John G Lawrenson, Yemisi Takwoingi, Noemi Lois
Cochrane Database of Systematic Reviews.2023;[Epub] CrossRef - Rapid Reduction of HbA1c and Early Worsening of Diabetic Retinopathy: A Real-world Population-Based Study in Subjects With Type 2 Diabetes
Rafael Simó, Josep Franch-Nadal, Bogdan Vlacho, Jordi Real, Ester Amado, Juana Flores, Manel Mata-Cases, Emilio Ortega, Mercedes Rigla, Joan-Anton Vallés, Cristina Hernández, Didac Mauricio
Diabetes Care.2023; 46(9): 1633. CrossRef - Minimum Effective Dose of DPP-4 Inhibitors for Treating Early Stages of Diabetic Retinopathy in an Experimental Model
Patricia Bogdanov, Hugo Ramos, Marta Valeri, Anna Deàs-Just, Jordi Huerta, Rafael Simó, Cristina Hernández
Biomedicines.2022; 10(2): 465. CrossRef - Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
Zaynab Ahmad Mouhammad, Rupali Vohra, Anna Horwitz, Anna-Sophie Thein, Jens Rovelt, Barbara Cvenkel, Pete A. Williams, Augusto Azuara-Blanco, Miriam Kolko
Frontiers in Neuroscience.2022;[Epub] CrossRef - Transcriptomic Analysis Reveals That Retinal Neuromodulation Is a Relevant Mechanism in the Neuroprotective Effect of Sitagliptin in an Experimental Model of Diabetic Retinopathy
Hugo Ramos, Patricia Bogdanov, Rafael Simó, Anna Deàs-Just, Cristina Hernández
International Journal of Molecular Sciences.2022; 24(1): 571. CrossRef - The Safety of Pharmacological and Surgical Treatment of Diabetes in Patients with Diabetic Retinopathy—A Review
Wojciech Matuszewski, Angelika Baranowska-Jurkun, Magdalena Maria Stefanowicz-Rutkowska, Katarzyna Gontarz-Nowak, Ewa Gątarska, Elżbieta Bandurska-Stankiewicz
Journal of Clinical Medicine.2021; 10(4): 705. CrossRef - Effects of Fibrates on Risk of Development of Diabetic Retinopathy in Japanese Working Age Patients with Type 2 Diabetes and Dyslipidemia: a Retrospective Cohort Study
Hayato Akimoto, Yasuo Takahashi, Satoshi Asai
YAKUGAKU ZASSHI.2021; 141(5): 761. CrossRef - Association between Add-On Dipeptidyl Peptidase-4 Inhibitor Therapy and Diabetic Retinopathy Progression
Eugene Yu-Chuan Kang, Chunya Kang, Wei-Chi Wu, Chi-Chin Sun, Kuan-Jen Chen, Chi-Chun Lai, Tien-Hsing Chen, Yih-Shiou Hwang
Journal of Clinical Medicine.2021; 10(13): 2871. CrossRef - Understanding molecular upsets in diabetic nephropathy to identify novel targets and treatment opportunities
Nidhi Raval, Akshant Kumawat, Dnyaneshwar Kalyane, Kiran Kalia, Rakesh K. Tekade
Drug Discovery Today.2020; 25(5): 862. CrossRef - Letter: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
Jun Sung Moon
Diabetes & Metabolism Journal.2019; 43(6): 911. CrossRef - Response: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
Yoo-Ri Chung, Kyoung Hwa Ha, Kihwang Lee, Dae Jung Kim
Diabetes & Metabolism Journal.2019; 43(6): 917. CrossRef
|
KDA
